SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rally to a 52-week high is driving discussion, with traders citing momentum and rotation into defensive, dividend-paying pharma amid broader market weakness. Bulls see a potential breakout, while skeptics point to resistance and say a fresh company-specific catalyst is needed.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly results beat expectations and the company raised its outlook, but shares fell as traders weighed rising costs, weaker cash flow and a loss in its insurance business. The reaction has split the community between buyers calling the selloff unjustified after a strong report and bears focused on the cost pressures and weak price action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is in focus amid volatile swings tied to a tech and AI-led selloff followed by a relief rebound. Traders disagree over whether the bounce can hold or is a bull trap, while concerns about AI funding and hedge-fund selling, rising oil and inflation, and upcoming megacap earnings add to uncertainty.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings and revenue beat and a new multiyear buyback, as traders focus on the narrowed profit outlook with its midpoint unchanged and declining U.S. sales and market share. Some see the decline as a buying opportunity given cash generation and capital returns, while others argue the outlook failed to justify the valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

NKTR advances rezpeg into phase III studies for atopic dermatitis, with additional autoimmune indications offering potential growth amid stiff competition.

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Equity

Nektar on Thursday announced data from two trials of its drug rezpegaldesleukin in alopecia and eczema. 


New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis...

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV...

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026PR NewswireSAN...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSAN FRANCISCO, Sept. 25, 2026 SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, Aug. 28, 2026 SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in...

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.

Retail Sales Weaken in July

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Bearish Sentiment

<ul class="summary-bullets"><li>Between week 36 and week 52 of the mid-stage REZOLVE-AA alopecia study, 29% of patients on the lower dose and 31% on the higher dose newly reached a level of hair coverage that leaves 20% or less of the scalp bare.</li><li>In the companion REZOLVE-AD study in moderate to severe atopic dermatitis, patients who switched to monthly or every-three-month injections largely held their gains in rash clearance and itch through week 52.</li><li>William Blair analyst Andy Hsieh kept an Outperform rating, saying the update adds to evidence that rezpeg has a material durability advantage over current standard treatments.</li></ul><p>Shares of Nektar Therapeutics (<a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a>) fell sharply by 21% on Thursday even as the company reported that its experimental skin drug, rezpegaldesleukin, kept working after treatment stopped, though the new response rates were modest and drawn from small patient groups.</p><p>The stock is now on track for its worst day since February 2023, if the losses hold. Analysts at William Blair and Jefferies, however, kept their bullish ratings on the stock.</p><h2 class="st-heading-2"><a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a>'s Alopecia Data&nbsp;</h2><p>Rezpegaldesleukin, or rezpeg, is designed to stimulate regulatory T cells, a part of the immune system that can calm attacks on the body’s own tissue. In severe alopecia areata, that attack strips hair from the scalp.</p><p>Between week 36 and week 52 of the mid-stage REZOLVE-AA alopecia study, 29% of patients on the lower dose and 31% on the higher dose newly reached a level of hair coverage that leaves 20% or less of the scalp bare. Those groups numbered only 14 and 13 patients. The claim that benefit held after dosing stopped rests on eight patients. None of the patients given a placebo newly reached the study’s main measure of success over that same stretch.</p><p>Among patients who had already responded after a year of treatment, 75% still met the threshold four months after stopping the drug, and 63% still did at six months, the company said.</p><p>Deeper regrowth, covering at least 90% of the scalp, rose from 7% at week 52 to 19% six months off treatment. Investigator David Rosmarin said existing systemic therapies have not shown this degree of lasting benefit and further regrowth after treatment ends. Safety through 52 weeks was described as favorable and consistent with earlier reports.</p><h2 class="st-heading-2">Eczema Trial Also Shows Improvement</h2><p>In the companion REZOLVE-AD study in moderate to severe atopic dermatitis, patients who switched to monthly or every-three-month injections largely held their gains in rash clearance and itch through week 52. The share reaching complete clearance rose several-fold on continued dosing.</p><p>Nektar has started a third late-stage eczema study in patients who already tried a biologic or a JAK inhibitor, and plans to open a roughly 850-patient late-stage alopecia trial, ZENITH-AA, in early 2027.</p><h2 class="st-heading-2"><a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> Analysts Disagree</h2><p>William Blair analyst Andy Hsieh kept an 'Outperform' rating on the stock, saying the update adds to evidence that rezpeg has a material durability advantage over current standard treatments. The firm pointed to an atopic dermatitis data update expected in the first quarter of 2027 as the next major catalyst.</p><p>Jefferies analyst Roger Song, meanwhile, called Thursday's selloff "unwarranted." The firm continues to see alopecia areata as "an underappreciated and untapped disease space" for rezpegaldesleukin. Jefferies has a $150 price target on the stock and a ‘Buy’ rating.</p><h2 class="st-heading-2">LLY Overhang On <a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> Stock</h2><p>A separate legal fight with Eli Lilly is still unresolved. The companies partnered in 2017 to develop rezpeg, but Lilly later bought a rival eczema drug and ended the deal. Nektar sued for about $1 billion; a jury in September awarded only $90 million plus interest, and Lilly plans to challenge the verdict, so the money is not yet in hand.</p><h2 class="st-heading-2">How Did <a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed ‘high.’</p><p>A Stocktwits user said the stock has been stuck for years, the recent win against Eli Lilly wasn't really a win, and the company has nothing new coming that would change that.</p><p><stembedurl>https://stocktwits.com/nab72/message/665553318</stembedurl></p><p>Another user, however, opined that Lilly might try to buy out Nektar.</p><p><stembedurl>https://stocktwits.com/george4it/message/665543981</stembedurl></p><p><a class="mention" data-mention="$NKTR" data-symbol-id="NKTR" href="https://stocktwits.com/symbol/NKTR" target="_blank">NKTR</a> stock has gained 12% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-could-face-an-faa-panel-on-software-glitch-this-week-as-max-10-certification-delay-holds-report/cZD0hEqRB0Q">Boeing Could Face An FAA Panel On Software Glitch This Week As Max 10 Certification Delay Holds: Report</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Between week 36 and week 52 of the mid-stage REZOLVE-AA alopecia study, 29% of patients on the lower dose and 31% on the higher dose newly reached a level of hair coverage that leaves 20% or less of the scalp bare.In the companion REZOLVE-AD study in mode

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$37.77
Prev Close	$36.64
Open	$36.98
Dividend Yield	0.00%
50-Day Moving Average	$62.22
Beta	1.73
Avg. Volume	1.36M
PE Ratio	-5.47

52-Week High	$109.00
52-Week Low	$33.40
Market Capitalization	$1.25B
EPS (Annual)	-$9.73
Price to Book	1.38
Revenue Per Employee	$876,698.41

Feed

News

Sentiment

Earnings

Fundamentals

Info

NKTR Fundamentals